Intra-Cellular Therapies Inc at JPMorgan Healthcare Conference Transcript
Great. Good morning, everyone. My name is Jess Fye. I'm one of the biotech analysts at JPMorgan, and we're continuing the 2020 Healthcare Conference this morning with Intra-Cellular, fresh on the heels of their recent drug approval.
We're going to do a Q&A session with the management team right after this. It's just down the hall in the Sussex room.
But for the presentation, I'm going to turn it over to the company's CEO, Sharon Mates.
Thanks, Jess, and welcome, everyone, to our presentation. So my presentation today does contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ. And I refer you to our website and to our SEC filings for continuous updates on the company.
So at Intra-Cellular Therapies, we started the company in 2002, and we started based on Nobel Prize-winning science and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
